RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC12H11NO

InChIKeyISWRGOKTTBVCFA-UHFFFAOYSA-N

CAS Registry53179-13-8

211

Clinical Trials associated with Pirfenidone

NCT06241560

/ Not yet recruitingPhase 2

An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another.
Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet.
Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.

Start Date20 Oct 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07141810

/ Not yet recruitingPhase 4IIT

Early Antifibrotic Therapy for f-ILD

Early antifibrotic therapy for f-ILD

Start Date01 Oct 2025

Sponsor / Collaborator

Shanghai Pulmonary Hospital

ChiCTR2500109774

/ Not yet recruitingPhase 2IIT

Exploratory Clinical Study of Camrelizumab Combined with Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Start Date30 Sep 2025

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Pirfenidone

100 Translational Medicine associated with Pirfenidone

100 Patents (Medical) associated with Pirfenidone

2,493

Literatures (Medical) associated with Pirfenidone

01 Dec 2025·Annals of Diagnostic Pathology

Relationship between fibroblastic foci and respiratory function: Does the abundance of fibroblastic foci reflect a recent decline in respiratory function?

Article

Author: Sakamoto, Ryo ; Nakajima, Daisuke ; Tanaka, Satona ; Handa, Tomohiro ; Date, Hiroshi ; Hamaji, Masatsugu ; Katsuragawa, Hiroyuki ; Haga, Hironori ; Ito, Hiroaki ; Yoshizawa, Akihiko

AIMS:

Fibroblastic foci (FF) are main findings in idiopathic pulmonary fibrosis (IPF) but are not specific to IPF. Pirfenidone and nintedanib are standard antifibrotic treatments for IPF and affect factors associated with fibroblasts. A proportion of interstitial lung diseases (ILDs) are progressive fibrosing ILDs (PF-ILDs). This progressive fibrosing phenotype includes various ILDs, including fibrotic hypersensitivity pneumonitis (FHP) and connective tissue disease-related ILD (CTD-ILD). We examined the relationship between FF and a relative decline in respiratory function.

METHODS AND RESULTS:

Among patients with lung transplantation (LT), those diagnosed with IPF, nonspecific interstitial pneumonia (NSIP), CTD-ILD, and FHP for whom respiratory function test results within 24 months before LT were retrospectively available were included (n = 67). Patients were classified as PF-ILD+ or PF-ILD- based on the criteria for the progression of a relative decline in the predicted value of forced vital capacity (FVC) within 24 months before LT. We classified FF into peripheral (pFF), alveolar (aFF), centrilobular (cFF), and distorted or dense fibrotic lesions (dFF). The number of FF/cm² at each location was counted, and its percentage was calculated. Spearman's rank correlation coefficient between a relative decline in %FVC and total FF/cm² in NSIP was 0.721. The dFF/cm² and dFF/total FF ratios were higher and the aFF/total FF ratio was lower in the PF-ILD+ group than in the PF-ILD- group.

CONCLUSION:

Total FF correlated with relative declines in %FVC in NSIP. Higher dFF/total FF ratios were associated with progressive status, and higher aFF/total FF ratios were associated with less progressive status.

01 Dec 2025·AUTOIMMUNITY REVIEWS

Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease

Review

Author: Mancuso, S ; De Lorenzis, E ; Manfredi, A ; Cozzini, F ; Radin, M ; Pollastri, F ; Carrara, G ; Landolfi, G ; Fassio, A ; Sebastiani, M ; Rozza, D ; Ughi, N ; Crotti, C

BACKGROUND:

rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Despite recent guideline initiatives, no treatment recommendations specifically tailored to RA-ILD have been developed in Italy. This systematic literature review (SLR) and meta-analysis was conducted to inform the Italian Society of Rheumatology (SIR) national recommendations for the management of RA-ILD.

METHODS:

we conducted a systematic review and meta-analysis of studies evaluating pharmacological interventions for RA-ILD from inception up to October 2023, followed by an update up to April 2025, with a pre-defined protocol. Eligible studies included randomized controlled trials, cohort studies, and case series reporting pulmonary function outcomes, radiological progression, adverse events, and mortality. Meta-analyses were performed, and heterogeneity and publication bias were thoroughly assessed.

RESULTS:

sixty-nine studies encompassing 7879 RA-ILD patients were included. Treatments with conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), rituximab (RTX), mycophenolate mofetil (MMF), abatacept (ABA), and Janus kinase inhibitors (JAKi) were associated with stabilization or improvement of forced vital capacity (FVC). Methotrexate (MTX) was associated with reduced risk of ILD progression and mortality. Antifibrotics, particularly nintedanib, demonstrated variable efficacy, while pirfenidone showed limited benefit. Safety profiles favored antifibrotics over csDMARDs/immunosuppressants regarding serious adverse events.

CONCLUSIONS:

this SLR provides an updated synthesis of evidence on RA-ILD treatments, supporting the forthcoming SIR recommendations. Despite inherent limitations of observational studies and heterogeneity, the data highlight the safety of MTX and particularly support ABA, RTX, and nintedanib as promising options, while underscoring the need for further high-quality trials specifically in RA-ILD.

01 Nov 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: A recent update

Review

Author: Kumari, Kajal ; Yadav, Richa ; Paliwal, Swati ; Sharma, Swapnil ; Verma, Kanika ; Sharma, Pragati ; Paliwal, Sarvesh

Pulmonary fibrosis (PF) is a chronic, progressive, and fatal lung disorder characterized by injury to alveolar epithelial cells (AECs), the formation of activated fibroblast/myofibroblast foci, and an excessive buildup of extracellular matrix (ECM). Current treatment strategies include the administration of two main drugs, viz., pirfenidone and nintedanib. However, there is no cure for PF; thus, there is a dire need to understand the pathophysiology of PF better and identify potential novel targets for PF. This review aims to provide a recent update on the signaling pathways contributing to the intricacies of cell signaling mechanisms driving fibrogenesis, including TGF-β, Hippo-YAP, NF-κB, inflammation, and Wnt/β-catenin. Additionally, the discussion covers emerging therapeutic strategies directed against such signaling networks, focusing on some of the most promising molecular strategies to halt or reverse fibrotic processes. Additionally, we discuss preclinical studies revealing the in vitro efficacy and safety, and the current clinical status of new therapeutic agents in PF. The synergy of preclinical and clinical studies' findings will allow this review to critically evaluate current therapeutic directions and emerging trends in PF management, shaping a future course of research and clinical application.

215

News (Medical) associated with Pirfenidone

15 Oct 2025

·www.globenewswire.com

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis. A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is designed to evaluate the efficacy and safety of 52 weeks of Pirfenidone capsule treatment in patients with pneumoconiosis, a chronic occupational lung disease characterized by progressive pulmonary fibrosis. Unmet Medical Need in Pneumoconiosis Pneumoconiosis remains the most common and severe occupational disease in China, with more than 450,000 surviving patients and thousands of new cases reported each year. It results from long-term inhalation of mineral dusts such as silica or coal, which triggers persistent inflammation and progressive fibrosis of the lung tissue. Over time, this excessive scar formation causes diffuse fibrosis and irreversible loss of lung function. Despite its prevalence and severity, there is currently no approved therapy in China that specifically targets the fibrotic mechanisms underlying pneumoconiosis. Based on recent expert consensus, China’s pneumoconiosis treatment landscape represents a significant unmet medical need, underscoring the importance of developing therapies specifically designed to slow or halt the progression of fibrosis and improve long-term outcomes for affected patients. About the 52-Week Phase 3 Trial The ongoing trial compares Pirfenidone 1,800 mg/day (600 mg tid) with placebo over a 52-week double-blind treatment period. Primary Endpoint: Change from baseline in forced vital capacity (FVC) % predicted at Week 52.Key Secondary Endpoints: Changes in diffusing capacity of the lungs for carbon monoxide (DLCO), 6-minute walk distance, St. George’s Respiratory Questionnaire (SGRQ) score, and Modified Medical Research Council (mMRC) dyspnea scale, as well as rates of acute exacerbations, hospitalizations, and deaths.Safety Monitoring: Follows Gyre’s Development Safety Update Report (DSUR Dec 2023–Dec 2024). Most adverse events reported to date are mild to moderate, with no unexpected safety signals.Interim Analysis: None planned. About Pirfenidone (ETUARY®) Pirfenidone is an oral antifibrotic small molecule that received its original approval in China in 2011 by Gyre Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF). It works by inhibiting TGF-β signaling and fibroblast proliferation. Gyre continues to advance Pirfenidone beyond IPF through multiple clinical programs, including the Phase 3 pneumoconiosis trial and the recently approved Phase 2/3 trial for oncology-related pulmonary complications such as radiation-induced lung injury (RILI) and checkpoint inhibitor pneumonitis (CIP). About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts, including Gyre’s advancement of its Phase 3 trial in China for Pirfenidone capsules for the treatment of pneumoconiosis and the initiation of Gyre’s Phase 2/3 trial in China for Pirfenidone capsules for the treatment of RILI and CIP; and trial design of Gyre’s Phase 3 trial in China for Pirfenidone capsules for the treatment of pneumoconiosis. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings with the Securities and Exchange Commission. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. For Investors:David Zhangdavid.zhang@gyretx.com

Phase 3

14 Oct 2025

·www.globenewswire.com

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it will be presenting results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent that inhibits hepatic stellate cell (HSC) activation and promotes HSC apoptosis, for the treatment of liver fibrosis in chronic hepatitis B, at The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting® 2025 is being held November 7-10, 2025, in Washington D.C. This abstract has been selected as a Poster of Distinction, and the details are below: Title: Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B Presenting Author: Prof. Lungen Lu, M.D., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Session: Hepatitis B (“1187-1367”) Date/Time: Friday, November 7, 2025, 8:00 a.m. – 5:00 p.m. Eastern Time Publication Number: 1121 About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230. For Investors: David ZhangGyre Therapeuticsdavid.zhang@gyretx.com

Phase 3Clinical Result

09 Oct 2025

·www.pharmaceutical-technology.com

Boehringer’s Jascayd nets first FDA IPF approval in over 10 years

German pharma Boehringer Ingelheim has obtained FDA approval for its disease-modifying therapy, Jascayd (nerandomalist) in IPF, making it the first treatment to be approved in this indication in more than a decade. Image credit: Fagreia via ShutterStock.com. Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making it the first drug to be approved in this indication in more than a decade. The preferential phosphodiesterase 4B (PDE4B) inhibitor is a first in its class that acts by exerting immunomodulatory and antifibrotic effects. These contribute to the slowing of lung function decline in patients. The drug obtained the FDA go-ahead after two positive Phase III readouts, including the FIBRONEER-ILD (NCT05321082) and FIBRONEER-IPF (NCT05321069) studies. During these trials, Jascayd was found to boost lung function by slowing forced vital capacity (FVC) decline. Following its market debut, Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, noted that Jascayd could fulfil the “long-standing need for new treatment options in IPF”. According to Staszak, the drug will also provide an important addition to IPF’s treatment landscape , which has lain dormant since the approval of anti-fibrotics pirfenidone and Boehringer’s Ofev (nintedanib), for which generics are now marketed. Jascayd could set a new standard in IPF Since the respective approvals of pirfenidone and nintedanib in IPF, these two drugs have been the standard of care (SoC) for patients, though they are commonly associated with strong side effects. This includes severe liver damage, meaning patients with compromised liver function may not be able to take this combination. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence According to analysts in GlobalData’s Immunology team, Jascayd approval will be a positive development for patients. “Jascayd is a new, effective treatment with a similar side effect profile to placebo,” which they note will be a welcome advance for those unable to tolerate currently approved therapies. Over time, analysts forecast that the drug will obtain patient share from pirfenidone-nintedanib, allowing the drug to “further penetrate the IPF market”. They also predict the drug’s clinical uptake to be swift, citing its “strong clinical backing and favourable safety profile,” as well as the “flexibility to use Jascayd alone or alongside existing treatment.” IPF market set for future growth Though the IPF market had not seen new blood since 2014, the indication’s dynamic appears to be shifting , as a big pharma and biotech push has seen a range of hopefuls reach late-stage trials. This includes Bristol Myers Squibb’s (BMS) admilparant, which is in a Phase III trial for IPF. In September 2025, United Therapeutics’ Tyvaso (inhaled treprostinil) showed benefit in the Phase III TETON-2 study (NCT05255991), with a significant 95.6mL increase in FVC from baseline. This data will tee the company up to apply for approval of the therapy in the US once it receives data from the TETON-1 trial (NCT04708782). EmphyCorp’s antioxidant, sodium pyruvate, is also in the registrational phase for IPF. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Phase 3Drug ApprovalClinical Result

100 Deals associated with Pirfenidone

External Link

KEGG	Wiki	ATC	Drug Bank
D01583	Pirfenidone	L04AX05	DB04951

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Japan	Shionogi & Co., Ltd.	16 Oct 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Interstitial lung disease due to systemic disease	Phase 3	China	GNI Group Ltd.	29 May 2023
Anthracosis	Phase 3	-	Beijing Kangdini Pharmaceutical Co., Ltd.	15 Apr 2022
Pneumoconiosis	Phase 3	-	Beijing Kangdini Pharmaceutical Co., Ltd.	15 Apr 2022
Silicosis	Phase 3	-	Beijing Kangdini Pharmaceutical Co., Ltd.	15 Apr 2022
Dermatomyositis	Phase 3	China	Beijing Kangdini Pharmaceutical Co., Ltd.	01 Jun 2018
Lung Diseases, Interstitial	Phase 3	China	Beijing Kangdini Pharmaceutical Co., Ltd.	31 Oct 2017
Sclerotylosis	Phase 3	China	Beijing Kangdini Pharmaceutical Co., Ltd.	31 Oct 2017
Progressive pulmonary fibrosis	Phase 2	United States	Avalyn Pharma Inc.	03 Apr 2024
Progressive pulmonary fibrosis	Phase 2	Argentina	Avalyn Pharma Inc.	03 Apr 2024
Progressive pulmonary fibrosis	Phase 2	Australia	Avalyn Pharma Inc.	03 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Idiopathic Pulmonary Fibrosis	4,529	Pirfenidone	dtbougrjzp(exzenroiwg) = tdalwqryps wwslpzqmur (utntyyornj )	Positive	30 May 2025
				Non-Pirfenidone	dtbougrjzp(exzenroiwg) = jvugqbakud wwslpzqmur (utntyyornj )
ATLAS Phase 1b Trial (ATS2025)	Phase 1	Idiopathic Pulmonary Fibrosis	64	Nebulised AP01 50mg QD	ixdekbewbn(jdtdslpsqo) = usbduxcitq omhdniafvg (tdcvdqzism ) View more	Positive	16 May 2025
				Nebulised AP01 100mg BID	ixdekbewbn(jdtdslpsqo) = hoyxnosxoc omhdniafvg (tdcvdqzism ) View more
AP01-002 (ATLAS) (ATS2025)	Not Applicable	-	91	50 mg AP01 once daily	bxcxuzphfv(lxvkggcdxi) = dlirmtqzxf mdekxdrnaj (zjcfdtlflj )	Positive	16 May 2025
				100 mg AP01 twice daily	bxcxuzphfv(lxvkggcdxi) = lipstcazrr mdekxdrnaj (zjcfdtlflj ) View more
ATLAS Phase 1b Trial (ATS2025)	Phase 1	-	28	AP01 50mg QD	cqatzdwypz(prpnmitevo) = ufzmnarbmc zdnxdppdln (hkxqucvwmj, 5.61)	Positive	16 May 2025
				AP01 100mg BID	cqatzdwypz(prpnmitevo) = bzrekgrwyf zdnxdppdln (hkxqucvwmj, 7.87)
ASTRO2024	Phase 2	Radiation Injuries	134	Pirfenidone plus standard therapy	noplkhpqsx(prkmbvclum) = pumryglcgz tmfrypxnyb (avwkfwzjuw ) View more	Positive	01 Oct 2024
WCLC2024	Phase 2	Lung Injury PD-1 inhibitors	14	Pirfenidone	teteknaapp(ewmhcsaemx) = Pirfenidone-related adverse events (≤ grade 2) occurred in 7 patients, including six gastrointestinal reactions and one photosensitivity reaction jmaqyolhyh (klqrdtlrdu )	Positive	07 Sep 2024
				Immune Checkpoint Inhibitors
NCT01366209 (ASCEND, Pubmed)	Phase 3	Idiopathic Pulmonary Fibrosis antinuclear antibodies (ANA) \| rheumatoid factor (RF) \| anti-cyclic citrullinated peptide (anti-CCP)	555	Pirfenidone	knohehqexw(wgxdcghqtl): HR = 0.56 (95% CI, 0.37 - 0.86), P-Value = 0.007	Positive	29 Jul 2024
				Placebo
ATS2024	Not Applicable	Idiopathic Pulmonary Fibrosis	-	Fybro® 400 mg	mqpimmaabd(imiaxxcxxh) = 16.5% rdsvrvysqk (icnubltniz ) View more	-	19 May 2024
ATLAS AP01 (ATS2024)	Phase 1	Idiopathic Pulmonary Fibrosis WRVS \| e-Lung volume	63	Nebulised Pirfenidone 100mg BD	vlyvecotez(gwboiytbwm) = lwtixrktrq yjrfdbskgz (alddtgtsky, -5.5% - +3.9) View more	Positive	19 May 2024
				Nebulised Pirfenidone 50mg OD	vlyvecotez(gwboiytbwm) = ifqkcmjice yjrfdbskgz (alddtgtsky, 1.2% - 9.5%) View more
NCT02622477 (AERplus, Pubmed \| Pneumologie) Manual	Not Applicable	Idiopathic Pulmonary Fibrosis	34	Pirfenidone	woxvgxsvrp(ainrodsltp) = gwrpfnriok azhiqxxlwm (iwwedazuzf ) View more	Positive	01 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis